Tags

Type your tag names separated by a space and hit enter

Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Pharmacol Ther 2017; 169:57-77P&T

Abstract

Eosinophils have been linked with asthma for more than a century, but their role has been unclear. This review discusses the roles of eosinophils in asthma and chronic obstructive pulmonary disease (COPD) and describes therapeutic antibodies that affect eosinophilia. The aims of pharmacologic treatments for pulmonary conditions are to reduce symptoms, slow decline or improve lung function, and reduce the frequency and severity of exacerbations. Inhaled corticosteroids (ICS) are important in managing symptoms and exacerbations in asthma and COPD. However, control with these agents is often suboptimal, especially for patients with severe disease. Recently, new biologics that target eosinophilic inflammation, used as adjunctive therapy to corticosteroids, have proven beneficial and support a pivotal role for eosinophils in the pathology of asthma. Nucala® (mepolizumab; anti-interleukin [IL]-5) and Cinquair® (reslizumab; anti-IL-5), the second and third biologics approved, respectively, for the treatment of asthma, exemplifies these new treatment options. Emerging evidence suggests that eosinophils may contribute to exacerbations and possibly to lung function decline for a subset of patients with COPD. Here we describe the pharmacology of therapeutic antibodies inhibiting IL-5 or targeting the IL-5 receptor, as well as other cytokines contributing to eosinophilic inflammation. We discuss their roles as adjuncts to conventional therapeutic approaches, especially ICS therapy, when disease is suboptimally controlled. These agents have achieved a place in the therapeutic armamentarium for asthma and COPD and will deepen our understanding of the pathogenic role of eosinophils.

Authors+Show Affiliations

MedImmune Ltd., Cambridge, UK.MedImmune LLC, Gaithersburg, MD, USA.MedImmune LLC, Gaithersburg, MD, USA.Lung Health Research Centre, University of Melbourne, Melbourne, Victoria, Australia.MedImmune LLC, Gaithersburg, MD, USA. Electronic address: KolbeckR@medimmune.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27773786

Citation

Nixon, John, et al. "Monoclonal Antibody Therapy for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Eosinophilic Inflammation." Pharmacology & Therapeutics, vol. 169, 2017, pp. 57-77.
Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57-77.
Nixon, J., Newbold, P., Mustelin, T., Anderson, G. P., & Kolbeck, R. (2017). Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacology & Therapeutics, 169, pp. 57-77. doi:10.1016/j.pharmthera.2016.10.016.
Nixon J, et al. Monoclonal Antibody Therapy for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Eosinophilic Inflammation. Pharmacol Ther. 2017;169:57-77. PubMed PMID: 27773786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. AU - Nixon,John, AU - Newbold,Paul, AU - Mustelin,Tomas, AU - Anderson,Gary P, AU - Kolbeck,Roland, Y1 - 2016/10/20/ PY - 2016/11/3/pubmed PY - 2017/8/8/medline PY - 2016/11/3/entrez KW - Asthma KW - Biologic therapy KW - Chronic obstructive pulmonary disease KW - Cytokines KW - Eosinophils KW - Interleukins SP - 57 EP - 77 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 169 N2 - Eosinophils have been linked with asthma for more than a century, but their role has been unclear. This review discusses the roles of eosinophils in asthma and chronic obstructive pulmonary disease (COPD) and describes therapeutic antibodies that affect eosinophilia. The aims of pharmacologic treatments for pulmonary conditions are to reduce symptoms, slow decline or improve lung function, and reduce the frequency and severity of exacerbations. Inhaled corticosteroids (ICS) are important in managing symptoms and exacerbations in asthma and COPD. However, control with these agents is often suboptimal, especially for patients with severe disease. Recently, new biologics that target eosinophilic inflammation, used as adjunctive therapy to corticosteroids, have proven beneficial and support a pivotal role for eosinophils in the pathology of asthma. Nucala® (mepolizumab; anti-interleukin [IL]-5) and Cinquair® (reslizumab; anti-IL-5), the second and third biologics approved, respectively, for the treatment of asthma, exemplifies these new treatment options. Emerging evidence suggests that eosinophils may contribute to exacerbations and possibly to lung function decline for a subset of patients with COPD. Here we describe the pharmacology of therapeutic antibodies inhibiting IL-5 or targeting the IL-5 receptor, as well as other cytokines contributing to eosinophilic inflammation. We discuss their roles as adjuncts to conventional therapeutic approaches, especially ICS therapy, when disease is suboptimally controlled. These agents have achieved a place in the therapeutic armamentarium for asthma and COPD and will deepen our understanding of the pathogenic role of eosinophils. SN - 1879-016X UR - https://www.unboundmedicine.com/medline/citation/27773786/Monoclonal_antibody_therapy_for_the_treatment_of_asthma_and_chronic_obstructive_pulmonary_disease_with_eosinophilic_inflammation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(16)30195-4 DB - PRIME DP - Unbound Medicine ER -